Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH

FOSTER CITY, Calif. & BAGSVÆRD, Denmark–(BUSINESS WIRE)–Nov. 15, 2020– Gilead Sciences, Inc. (Nasdaq: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced results from a Phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor firsocostat…

Wearable Sensor Data Predict Heart Failure Rehospitalization

TUESDAY, Feb. 25, 2020 — For patients discharged from heart failure admission, analysis of physiological telemetry data from a wearable sensor can detect worsening heart failure and predict impending rehospitalization, according to a study published online Feb. 25 in Circulation: Heart Failure. Josef Stehlik, M.D., M.P.H., from the VA Salt…

Sharing data with surgeons can reduce overuse of Mohs surgery

(HealthDay)—Sharing personalized practice pattern data with physicians that is benchmarked to national data for their peers can reduce overuse of Mohs micrographic surgery (MMS) among outliers, according to a study published online May 5 in JAMA Dermatology. John G. Albertini, M.D., from The Skin Surgery Center in Winston Salem, North…